 [1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ATENOLOL increase the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ATENOLOL increase the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ATENOLOL increase the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ATENOLOL"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m            No extracts found! You can try doing a web search with the[0m
[31m            `relevant_search_extracts` or `drug_category_search`[0m
[31m            tools/function-calls.[0m
[31m            [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ATENOLOL increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ATENOLOL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ATENOLOL: adverse_reactions: ADVERSE REACTIONS Most adverse effects have been mild and transient. The frequency estimates in the following table were derived from controlled studies in [0m
[31mhypertensive patients in which adverse reactions were either volunteered by the patient [0m[1;31m([0m[31mUS studies[0m[1;31m)[0m[31m or elicited, e.g., by checklist [0m[1;31m([0m[31mforeign studies[0m[1;31m)[0m[31m. The reported frequency of elicited adverse [0m
[31meffects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered. Where frequency of adverse effects of atenolol and placebo is similar, causal relationship[0m
[31mto atenolol is uncertain. Volunteered [0m[1;31m([0m[31m US Studies [0m[1;31m)[0m[31m Total-Volunteered and Elicited [0m[1;31m([0m[31m Foreign + US Studies [0m[1;31m)[0m[31m Atenolol [0m[1;31m([0m[31mn = [0m[1;31m164[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m206[0m[1;31m)[0m[31m % Atenolol [0m[1;31m([0m[31mn = [0m[1;31m399[0m[1;31m)[0m[31m % Placebo [0m[1;31m([0m[31mn = [0m[1;31m407[0m[1;31m)[0m[31m % [0m
[31mCARDIOVASCULAR Bradycardia [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0[0m[31m Cold Extremities [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m5[0m[31m Postural Hypotension [0m[1;31m2[0m[31m [0m[1;31m1[0m[31m [0m[1;31m4[0m[31m [0m[1;31m5[0m[31m Leg Pain [0m[1;31m0[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Dizziness [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m13[0m[31m [0m[1;31m6[0m[31m [0m
[31mVertigo [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.2[0m[31m Lightheadedness [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Tiredness [0m[1;31m0.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m26[0m[31m [0m[1;31m13[0m[31m Fatigue [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m5[0m[31m Lethargy [0m[1;31m1[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m0.7[0m[31m Drowsiness [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m [0m[1;31m2[0m[31m [0m[1;31m0.5[0m[31m Depression [0m[1;31m0.6[0m[31m [0m[1;31m0[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m5[0m[31m [0m[1;31m12[0m[31m [0m[1;31m9[0m[31m Dreaming [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m [0m
[31mGASTROINTESTINAL Diarrhea [0m[1;31m2[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m2[0m[31m Nausea [0m[1;31m4[0m[31m [0m[1;31m1[0m[31m [0m[1;31m3[0m[31m [0m[1;31m1[0m[31m RESPIRATORY [0m[1;31m([0m[31msee WARNINGS[0m[1;31m)[0m[31m Wheeziness [0m[1;31m0[0m[31m [0m[1;31m0[0m[31m [0m[1;31m3[0m[31m [0m[1;31m3[0m[31m Dyspnea [0m[1;31m0.6[0m[31m [0m[1;31m1[0m[31m [0m[1;31m6[0m[31m [0m[1;31m4[0m[31m Acute Myocardial Infarction In a series of investigations in the treatment of acute [0m
[31mmyocardial infarction, bradycardia and hypotension occurred more commonly, as expected for any beta blocker, in atenolol-treated patients than in control patients. However, these usually responded to [0m
[31matropine and/or to withholding further dosage of atenolol. The incidence of heart failure was not increased by atenolol. Inotropic agents were infrequently used. The reported frequency of these and [0m
[31mother events occurring during these investigations is given in the following table. ATENOLOL: adverse_reactions: In a study of [0m[1;31m477[0m[31m patients, the following adverse events were reported during either [0m
[31mintravenous and/or oral atenolol administration: Conventional Therapy Plus Atenolol [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m244[0m[1;31m)[0m[31m Conventional Therapy Alone [0m[1;31m([0m[31mn[0m[31m=[0m[1;31m233[0m[1;31m)[0m[31m Bradycardia [0m[1;31m43[0m[31m [0m[1;31m([0m[1;31m18[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m24[0m[31m [0m[1;31m([0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m Hypotension [0m[1;31m60[0m[31m [0m[1;31m([0m[1;31m25[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m34[0m[31m [0m[1;31m([0m[1;31m15[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m
[1;31m3[0m[31m [0m[1;31m([0m[1;31m1.2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Heart Failure [0m[1;31m46[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m56[0m[31m [0m[1;31m([0m[1;31m24[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m11[0m[31m [0m[1;31m([0m[1;31m4.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m10[0m[31m [0m[1;31m([0m[1;31m4.3[0m[31m%[0m[1;31m)[0m[31m BBB + Major Axis Deviation [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m12[0m[31m%[0m[1;31m)[0m[31m Supraventricular Tachycardia [0m[1;31m28[0m[31m [0m[1;31m([0m[1;31m11.5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m45[0m[31m [0m[1;31m([0m[1;31m19[0m[31m%[0m[1;31m)[0m[31m Atrial Fibrillation [0m[1;31m12[0m[31m [0m
[1;31m([0m[1;31m5[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m29[0m[31m [0m[1;31m([0m[1;31m11[0m[31m%[0m[1;31m)[0m[31m Atrial Flutter [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m3[0m[31m%[0m[1;31m)[0m[31m Ventricular Tachycardia [0m[1;31m39[0m[31m [0m[1;31m([0m[1;31m16[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m52[0m[31m [0m[1;31m([0m[1;31m22[0m[31m%[0m[1;31m)[0m[31m Cardiac Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m6[0m[31m [0m[1;31m([0m[1;31m2.6[0m[31m%[0m[1;31m)[0m[31m Total Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m [0m
[31mNonfatal Cardiac Arrests [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.6[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m12[0m[31m [0m[1;31m([0m[1;31m5.1[0m[31m%[0m[1;31m)[0m[31m Deaths [0m[1;31m7[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m16[0m[31m [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m Cardiogenic Shock [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m4[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Development of Ventricular Septal Defect [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Development of Mitral Regurgitation [0m[1;31m0[0m
[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m2[0m[31m [0m[1;31m([0m[1;31m0.9[0m[31m%[0m[1;31m)[0m[31m Renal Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[1;31m0.4[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m Pulmonary Emboli [0m[1;31m3[0m[31m [0m[1;31m([0m[1;31m1[0m[31m. ATENOLOL: adverse_reactions: [0m[1;31m2[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m In the subsequent International Study of Infarct Survival [0m[1;31m([0m[31mISIS-[0m[1;31m1[0m[1;31m)[0m[31m including over [0m[1;31m16[0m[31m,[0m[1;31m000[0m[31m [0m
[31mpatients of whom [0m[1;31m8[0m[31m,[0m[1;31m037[0m[31m were randomized to receive atenolol treatment, the dosage of intravenous and subsequent oral atenolol was either discontinued or reduced for the following reasons: Reasons for [0m
[31mReduced Dosage IV Atenolol Reduced [0m[1;31mDose[0m[1;31m([0m[1;31m<[0m[31m [0m[1;31m5[0m[31m mg[0m[1;31m)[0m[31m Full dosage was [0m[1;31m10[0m[31m mg and some patients received less than [0m[1;31m10[0m[31m mg but more than [0m[1;31m5[0m[31m mg. Oral Partial Dose Hypotension [0m[31m/[0m[31m Bradycardia [0m[1;31m105[0m[31m [0m[1;31m([0m[1;31m1.3[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m1168[0m[31m [0m[1;31m([0m[1;31m14.5[0m[31m%[0m[1;31m)[0m
[31mCardiogenic Shock [0m[1;31m4[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m35[0m[31m [0m[1;31m([0m[31m.[0m[1;31m44[0m[31m%[0m[1;31m)[0m[31m Reinfarction [0m[1;31m0[0m[31m [0m[1;31m([0m[1;31m0[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m Cardiac Arrest [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m28[0m[31m [0m[1;31m([0m[31m.[0m[1;31m34[0m[31m%[0m[1;31m)[0m[31m Heart Block [0m[1;31m([0m[1;31m>[0m[31m first degree[0m[1;31m)[0m[31m [0m[1;31m5[0m[31m [0m[1;31m([0m[31m.[0m[1;31m06[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m143[0m[31m [0m[1;31m([0m[1;31m1.7[0m[31m%[0m[1;31m)[0m[31m Cardiac Failure [0m[1;31m1[0m[31m [0m[1;31m([0m[31m. ATENOLOL: adverse_reactions: [0m
[1;31m01[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m233[0m[31m [0m[1;31m([0m[1;31m2.9[0m[31m%[0m[1;31m)[0m[31m Arrhythmias [0m[1;31m3[0m[31m [0m[1;31m([0m[31m.[0m[1;31m04[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m22[0m[31m [0m[1;31m([0m[31m.[0m[1;31m27[0m[31m%[0m[1;31m)[0m[31m Bronchospasm [0m[1;31m1[0m[31m [0m[1;31m([0m[31m.[0m[1;31m01[0m[31m%[0m[1;31m)[0m[31m [0m[1;31m50[0m[31m [0m[1;31m([0m[31m.[0m[1;31m62[0m[31m%[0m[1;31m)[0m[31m During postmarketing experience with atenolol, the following have been reported in temporal relationship to the use of [0m
[31mthe drug: elevated liver enzymes and/or bilirubin, hallucinations, headache, impotence, Peyronie's disease, postural hypotension which may be associated with syncope, psoriasiform rash or exacerbation[0m
[31mof psoriasis, psychoses, purpura, reversible alopecia, thrombocytopenia, visual disturbance, sick sinus syndrome, and dry mouth. Atenolol, like other beta blockers, has been associated with the [0m
[31mdevelopment of antinuclear antibodies [0m[1;31m([0m[31mANA[0m[1;31m)[0m[31m, lupus syndrome, and Raynaud’s phenomenon.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ATENOLOL: precautions: Information on concurrent usage of atenolol and aspirin is limited. Data from several studies, i.e., TIMI-II, ISIS-[0m[1;31m2[0m[31m, currently do not suggest any clinical interaction [0m
[31mbetween aspirin and beta blockers in the acute myocardial infarction setting. While taking beta blockers, patients with a history of anaphylactic reaction to a variety of allergens may have a more [0m
[31msevere reaction on repeated challenge, either accidental, diagnostic or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat the allergic reaction. Both [0m
[31mdigitalis glycosides and beta blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. ATENOLOL: precautions: Carcinogenesis, [0m
[31mMutagenesis, Impairment of Fertility Two long-term [0m[1;31m([0m[31mmaximum dosing duration of [0m[1;31m18[0m[31m or [0m[1;31m24[0m[31m months[0m[1;31m)[0m[31m rat studies and one long-term [0m[1;31m([0m[31mmaximum dosing duration of [0m[1;31m18[0m[31m months[0m[1;31m)[0m[31m mouse study, each employing dose [0m
[31mlevels as high as [0m[1;31m300[0m[31m mg/kg/day or [0m[1;31m150[0m[31m times the maximum recommended human antihypertensive dose * , did not indicate a carcinogenic potential of atenolol. A third [0m[1;31m([0m[1;31m24[0m[31m month[0m[1;31m)[0m[31m rat study, employing [0m
[31mdoses of [0m[1;31m500[0m[31m and [0m[1;31m1[0m[31m,[0m[1;31m500[0m[31m mg/kg/day [0m[1;31m([0m[1;31m250[0m[31m and [0m[1;31m750[0m[31m times the maximum recommended human antihypertensive dose * [0m[1;31m)[0m[31m resulted in increased incidences of benign adrenal medullary tumors in males and females, [0m
[31mmammary fibroadenomas in females, and anterior pituitary adenomas and thyroid parafollicular cell carcinomas in males. ATENOLOL: precautions: No evidence of a mutagenic potential of atenolol was [0m
[31muncovered in the dominant lethal test [0m[1;31m([0m[31mmouse[0m[1;31m)[0m[31m, in vivo cytogenetics test [0m[1;31m([0m[31mChinese hamster[0m[1;31m)[0m[31m or Ames test [0m[1;31m([0m[31mS. typhimurium[0m[1;31m)[0m[31m. Fertility of male or female rats [0m[1;31m([0m[31mevaluated at dose levels as high as [0m[1;31m200[0m[31m [0m
[31mmg/kg/day or [0m[1;31m100[0m[31m times the maximum recommended human dose * [0m[1;31m)[0m[31m was unaffected by atenolol administration. Animal Toxicology Chronic studies employing oral atenolol performed in animals have revealed [0m
[31mthe occurrence of vacuolation of epithelial cells of Brunner's glands in the duodenum of both male and female dogs at all tested dose levels of atenolol [0m[1;31m([0m[31mstarting at [0m[1;31m15[0m[31m mg/kg/day or [0m[1;31m7[0m[31m. ATENOLOL: [0m
[31mprecautions: [0m[1;31m5[0m[31m times the maximum recommended human antihypertensive dose * [0m[1;31m)[0m[31m and increased incidence of atrial degeneration of hearts of male rats at [0m[1;31m300[0m[31m but not [0m[1;31m150[0m[31m mg atenolol/kg/day [0m[1;31m([0m[1;31m150[0m[31m and [0m[1;31m75[0m[31m [0m
[31mtimes the maximum recommended human antihypertensive dose * , respectively[0m[1;31m)[0m[31m. ________________________________________________________________________ * Based on the maximum dose of [0m[1;31m100[0m[31m mg/day in a [0m[1;31m50[0m[31m [0m
[31mkg patient. Usage in Pregnancy Pregnancy Category D : See WARNINGS - Pregnancy and Fetal Injury. Nursing Mothers Atenolol is excreted in human breast milk at a ratio of [0m[1;31m1.5[0m[31m to [0m[1;31m6.8[0m[31m when compared to the[0m
[31mconcentration in plasma. Caution should be exercised when atenolol is administered to a nursing woman. Clinically significant bradycardia has been reported in breast fed infants. Premature infants, or[0m
[31minfants with impaired renal function, may be more likely to develop adverse effects. ATENOLOL: precautions: Neonates born to mothers who are receiving atenolol at parturition or breast-feeding may be [0m
[31mat risk for hypoglycemia and bradycardia. Caution should be exercised when atenolol is administered during pregnancy or to a woman who is breast-feeding [0m[1;31m([0m[31msee WARNING, Pregnancy and Fetal Injury [0m[1;31m)[0m[31m. [0m
[31mPediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use Hypertension and Angina Pectoris Due to Coronary Atherosclerosis Clinical studies of atenolol did [0m
[31mnot include sufficient number of patients aged [0m[1;31m65[0m[31m and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in [0m
[31mresponses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater [0m
[31mfrequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: LISINOPRIL: warnings: WARNINGS General Lisinopril Anaphylactoid and Possibly Related Reactions: Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of [0m
[31meicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors [0m[1;31m([0m[31mincluding lisinopril and hydrochlorothiazide tablets[0m[1;31m)[0m[31m may be subject to a variety of adverse [0m
[31mreactions, some of them serious. Head and Neck Angioedema: Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely in patients treated with angiotensin [0m
[31mconverting enzyme inhibitors, including lisinopril. This may occur at any time during treatment. ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black [0m
[31mpatients. LISINOPRIL: warnings: In such cases lisinopril and hydrochlorothiazide tablets should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and [0m
[31msustained resolution of signs and symptoms has occurred. Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation[0m
[31msince treatment with antihistamines and corticosteroids may not be sufficient. Very rarely, fatalities have been reported due to angioedema associated with laryngeal edema or tongue edema. Patients [0m
[31mwith involvement of the tongue, glottis or larynx are likely to experience airway obstruction, especially those with a history of airway surgery. Where there is involvement of the tongue, glottis or [0m
[31mlarynx, likely to cause airway obstruction, subcutaneous epinephrine solution [0m[1;31m1:1000[0m[31m [0m[1;31m([0m[1;31m0.3[0m[31m mL to [0m[1;31m0[0m[31m. LISINOPRIL: warnings: [0m[1;31m5[0m[31m mL[0m[1;31m)[0m[31m and/or measures necessary to ensure a patent airway should be promptly [0m
[31mprovided [0m[1;31m([0m[31mSee ADVERSE REACTIONS . [0m[1;31m)[0m[31m Patients with a history of angioedema unrelated to ACE-inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor [0m[1;31m([0m[31msee also [0m
[31mINDICATIONS AND USAGE and CONTRAINDICATIONS [0m[1;31m)[0m[31m. Patients receiving coadministration of ACE inhibitor and mTOR [0m[1;31m([0m[31mmammalian target of rapamycin[0m[1;31m)[0m[31m inhibitor [0m[1;31m([0m[31me.g., temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m [0m
[31mtherapy or a neprilysin inhibitor may be at increased risk for angioedema [0m[1;31m([0m[31msee PRECAUTIONS [0m[1;31m)[0m[31m. Intestinal Angioedema : Intestinal angioedema has been reported in patients treated with ACE inhibitors. [0m
[31mThese patients presented with abdominal pain [0m[1;31m([0m[31mwith or without nausea or vomiting[0m[1;31m)[0m[31m; in some cases there was no prior history of facial angioedema and C-[0m[1;31m1[0m[31m esterase levels were normal. LISINOPRIL: [0m
[31mwarnings: The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be [0m
[31mincluded in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain. Anaphylactoid reactions during desensitization: Two patients undergoing desensitizing treatment [0m
[31mwith hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily [0m
[31mwithheld, but they reappeared upon inadvertent rechallenge. Anaphylactoid reactions during membrane exposure: Sudden and potentially life-threatening anaphylactoid reactions have been reported in some[0m
[31mpatients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. In such patients, dialysis must be stopped immediately, and aggressive therapy for anaphylactoid reactions [0m
[31mmust be initiated. LISINOPRIL: warnings: Symptoms have not been relieved by antihistamines in these situations. In these patients, consideration should be given to using a different type of dialysis [0m
[31mmembrane or a different class of antihypertensive agent. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. [0m
[31mHypotension and Related Effects Excessive hypotension was rarely seen in uncomplicated hypertensive patients but is a possible consequence of lisinopril use in salt/volume-depleted persons such as [0m
[31mthose treated vigorously with diuretics or patients on dialysis. [0m[1;31m([0m[31mSee PRECAUTIONS, Drug Interactions and ADVERSE REACTIONS .[0m[1;31m)[0m[31m Syncope has been reported in [0m[1;31m0.8[0m[31m percent of patients receiving lisinopril [0m
[31mand hydrochlorothiazide tablets. In patients with hypertension receiving lisinopril alone, the incidence of syncope was [0m[1;31m0.1[0m[31m percent.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: ATENOLOL: pharmacodynamics: Pharmacodynamics In standard animal or human pharmacological tests, beta-adrenoreceptor blocking activity of atenolol has been demonstrated by: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m reduction in [0m
[31mresting and exercise heart rate and cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m reduction of systolic and diastolic blood pressure at rest and on exercise, [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m inhibition of isoproterenol induced tachycardia, and [0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m [0m
[31mreduction in reflex orthostatic tachycardia. A significant beta-blocking effect of atenolol, as measured by reduction of exercise tachycardia, is apparent within one hour following oral administration[0m
[31mof a single dose. This effect is maximal at about [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m hours, and persists for at least [0m[1;31m24[0m[31m hours. Maximum reduction in exercise tachycardia occurs within [0m[1;31m5[0m[31m minutes of an intravenous dose. ATENOLOL: [0m
[31mpharmacodynamics: For both orally and intravenously administered drug, the duration of action is dose related and also bears a linear relationship to the logarithm of plasma atenolol concentration. [0m
[31mThe effect on exercise tachycardia of a single [0m[1;31m10[0m[31m mg intravenous dose is largely dissipated by [0m[1;31m12[0m[31m hours, whereas beta-blocking activity of single oral doses of [0m[1;31m50[0m[31m mg and [0m[1;31m100[0m[31m mg is still evident beyond[0m
[1;31m24[0m[31m hours following administration. However, as has been shown for all beta-blocking agents, the antihypertensive effect does not appear to be related to plasma level. In normal subjects, the beta1 [0m
[31mselectivity of atenolol has been shown by its reduced ability to reverse the beta2-mediated vasodilating effect of isoproterenol as compared to equivalent betab-locking doses of propranolol. ATENOLOL:[0m
[31mpharmacodynamics: In asthmatic patients, a dose of atenolol producing a greater effect on resting heart rate than propranolol resulted in much less increase in airway resistance. In a placebo [0m
[31mcontrolled comparison of approximately equipotent oral doses of several beta blockers, atenolol produced a significantly smaller decrease of FEV1 than nonselective beta blockers such as propranolol [0m
[31mand, unlike those agents, did not inhibit bronchodilation in response to isoproterenol. Consistent with its negative chronotropic effect due to beta blockade of the SA node, atenolol increases sinus [0m
[31mcycle length and sinus node recovery time. Conduction in the AV node is also prolonged. Atenolol is devoid of membrane stabilizing activity, and increasing the dose well beyond that producing beta [0m
[31mblockade does not further depress myocardial contractility. Several studies have demonstrated a moderate [0m[1;31m([0m[31mapproximately [0m[1;31m10[0m[31m%[0m[1;31m)[0m[31m increase in stroke volume at rest and during exercise. ATENOLOL: [0m
[31mpharmacodynamics: In controlled clinical trials, atenolol, given as a single daily oral dose, was an effective antihypertensive agent providing [0m[1;31m24[0m[31m-hour reduction of blood pressure. Atenolol has been [0m
[31mstudied in combination with thiazide-type diuretics, and the blood pressure effects of the combination are approximately additive. Atenolol is also compatible with methyldopa, hydralazine, and [0m
[31mprazosin, each combination resulting in a larger fall in blood pressure than with the single agents. The dose range of atenolol is narrow and increasing the dose beyond [0m[1;31m100[0m[31m mg once daily is not [0m
[31massociated with increased antihypertensive effect. The mechanisms of the antihypertensive effects of beta-blocking agents have not been established. ATENOLOL: pharmacodynamics: Several possible [0m
[31mmechanisms have been proposed and include: [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m competitive antagonism of catecholamines at peripheral [0m[1;31m([0m[31mespecially cardiac[0m[1;31m)[0m[31m adrenergic neuron sites, leading to decreased cardiac output, [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m a central [0m
[31meffect leading to reduced sympathetic outflow to the periphery, and [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m suppression of renin activity. The results from long-term studies have not shown any diminution of the antihypertensive efficacy[0m
[31mof atenolol with prolonged use. By blocking the positive chronotropic and inotropic effects of catecholamines and by decreasing blood pressure, atenolol generally reduces the oxygen requirements of [0m
[31mthe heart at any given level of effort, making it useful for many patients in the long-term management of angina pectoris. On the other hand, atenolol can increase oxygen requirements by increasing [0m
[31mleft ventricular fiber length and end diastolic pressure, particularly in patients with heart failure.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m


[31mCONTENT: ENALAPRIL MALEATE: precautions: Monitor renal function periodically in patients receiving enalapril and NSAID therapy. In a clinical pharmacology study, indomethacin or sulindac was [0m
[31madministered to hypertensive patients receiving enalapril maleate. In this study there was no evidence of a blunting of the antihypertensive action of enalapril maleate. However, reports suggest that [0m
[31mNSAIDs may diminish the antihypertensive effect of ACE inhibitors. Other Cardiovascular Agents Enalapril maleate has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates,[0m
[31mcalcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions. Agents Increasing Serum Potassium Enalapril attenuates potassium loss caused[0m
[31mby thiazide-type diuretics. Potassium-sparing diuretics [0m[1;31m([0m[31me.g. ENALAPRIL MALEATE: precautions: spironolactone, triamterene, or amiloride[0m[1;31m)[0m[31m, potassium supplements, or potassium-containing salt [0m
[31msubstitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and [0m
[31mwith frequent monitoring of serum potassium. Potassium-sparing agents should generally not be used in patients with heart failure receiving enalapril maleate. Lithium Lithium toxicity has been [0m
[31mreported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of lithium toxicity have been reported in patients receiving [0m
[31mconcomitant enalapril maleate and lithium and were reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if enalapril is administered [0m
[31mconcomitantly with lithium. ENALAPRIL MALEATE: precautions: Gold Nitritoid reactions [0m[1;31m([0m[31msymptoms include facial flushing, nausea, vomiting and hypotension[0m[1;31m)[0m[31m have been reported rarely in patients on [0m
[31mtherapy with injectable gold [0m[1;31m([0m[31msodium aurothiomalate[0m[1;31m)[0m[31m and concomitant ACE inhibitor therapy including enalapril maleate. mTOR [0m[1;31m([0m[31mMammalian Target of Rapamycin[0m[1;31m)[0m[31m Inhibitors Patients receiving [0m
[31mcoadministration of ACE inhibitor and mTOR inhibitor [0m[1;31m([0m[31me.g., temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m therapy may be at increased risk for angioedema [0m[1;31m([0m[31msee WARNINGS, Head and Neck Angioedema [0m[1;31m)[0m[31m. [0m
[31mCarcinogenesis, Mutagenesis, Impairment of Fertility There was no evidence of a tumorigenic effect when enalapril was administered for [0m[1;31m106[0m[31m weeks to male and female rats at doses up to [0m[1;31m90[0m[31m mg/kg/day or [0m
[31mfor [0m[1;31m94[0m[31m weeks to male and female mice at doses up to [0m[1;31m90[0m[31m and [0m[1;31m180[0m[31m mg/kg/day, respectively. ENALAPRIL MALEATE: precautions: These doses are [0m[1;31m26[0m[31m times [0m[1;31m([0m[31min rats and female mice[0m[1;31m)[0m[31m and [0m[1;31m13[0m[31m times [0m[1;31m([0m[31min male mice[0m[1;31m)[0m[31m [0m
[31mthe maximum recommended human daily dose [0m[1;31m([0m[31mMRHDD[0m[1;31m)[0m[31m when compared on a body surface area basis. Neither enalapril maleate nor the active diacid was mutagenic in the Ames microbial mutagen test with or [0m
[31mwithout metabolic activation. Enalapril was also negative in the following genotoxicity studies: rec-assay, reverse mutation assay with E. coli , sister chromatid exchange with cultured mammalian [0m
[31mcells, and the micronucleus test with mice, as well as in an in vivo cytogenic study using mouse bone marrow. There were no adverse effects on reproductive performance of male and female rats treated [0m
[31mwith up to [0m[1;31m90[0m[31m mg/kg/day of enalapril [0m[1;31m([0m[1;31m26[0m[31m times the MRHDD when compared on a body surface area basis[0m[1;31m)[0m[31m. Pregnancy Nursing Mothers Enalapril and enalaprilat have been detected in human breast milk. [0m
[31mENALAPRIL MALEATE: precautions: Because of the potential for serious adverse reactions in nursing infants from enalapril, a decision should be made whether to discontinue nursing or to discontinue [0m
[31menalapril maleate, taking into account the importance of the drug to the mother. Pediatric Use Neonates with a History of In Utero Exposure to Enalapril Maleate If oliguria or hypotension occurs, [0m
[31mdirect attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal [0m
[31mfunction. Enalapril, which crosses the placenta, has been removed from neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange transfusion,[0m
[31malthough there is no experience with the latter procedure. Antihypertensive effects of enalapril maleate have been established in hypertensive pediatric patients age [0m[1;31m1[0m[31m month to [0m[1;31m16[0m[31m years.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: drug_interactions: Drug Interactions Neprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Dual [0m
[31mBlockade of the Renin-Angiotensin System [0m[1;31m([0m[31mRAS[0m[1;31m)[0m[31m Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, [0m
[31mhyperkalemia, and changes in renal function [0m[1;31m([0m[31mincluding acute renal failure[0m[1;31m)[0m[31m compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit [0m
[31mcompared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function, and electrolytes in patients on enalapril maleate and other agents that [0m
[31maffect the RAS. Do not coadminister aliskiren with enalapril maleate in patients with diabetes. ENALAPRIL MALEATE: drug_interactions: Avoid use of aliskiren with enalapril maleate in patients with [0m
[31mrenal impairment [0m[1;31m([0m[31mGFR <[0m[1;31m60[0m[31m mL/min[0m[1;31m)[0m[31m. Hypotension—Patients on Diuretic Therapy Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an [0m
[31mexcessive reduction of blood pressure after initiation of therapy with enalapril. The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or [0m
[31mincreasing the salt intake prior to initiation of treatment with enalapril. If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours[0m
[31mand until blood pressure has stabilized for at least an additional hour [0m[1;31m([0m[31msee WARNINGS , Hypotension and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Agents Causing Renin Release The antihypertensive effect of [0m
[31menalapril maleate is augmented by antihypertensive agents that cause renin release [0m[1;31m([0m[31me. ENALAPRIL MALEATE: drug_interactions: ., diuretics[0m[1;31m)[0m[31m. Nonsteroidal Anti-Inflammatory Agents Including Selective [0m
[31mCyclooxygenase-[0m[1;31m2[0m[31m Inhibitors [0m[1;31m([0m[31mCOX-[0m[1;31m2[0m[31m Inhibitors[0m[1;31m)[0m[31m In patients who are elderly, volume-depleted [0m[1;31m([0m[31mincluding those on diuretic therapy[0m[1;31m)[0m[31m, or with compromised renal function, coadministration of NSAIDs, [0m
[31mincluding selective COX-[0m[1;31m2[0m[31m inhibitors, with ACE inhibitors, including enalapril, may result in deterioration of renal function, including possible acute renal failure. These effects are usually [0m
[31mreversible. Monitor renal function periodically in patients receiving enalapril and NSAID therapy. In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients [0m
[31mreceiving enalapril maleate. In this study there was no evidence of a blunting of the antihypertensive action of enalapril maleate. However, reports suggest that NSAIDs may diminish the [0m
[31mantihypertensive effect of ACE inhibitors.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: precautions: ACE inhibitor-induced cough should be considered in the differential diagnosis of cough. Surgery/Anesthesia In patients undergoing major surgery or during [0m
[31manesthesia with agents that produce hypotension, enalapril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this [0m
[31mmechanism, it can be corrected by volume expansion. Information for Patients Angioedema Angioedema, including laryngeal edema, may occur at any time during treatment with angiotensin-converting enzyme[0m
[31minhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema [0m[1;31m([0m[31mswelling of face, extremities, eyes, lips, tongue, difficulty[0m
[31min swallowing or breathing[0m[1;31m)[0m[31m and to take no more drug until they have consulted with the prescribing physician. Hypotension Patients should be cautioned to report lightheadedness, especially during the[0m
[31mfirst few days of therapy. ENALAPRIL MALEATE: precautions: If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician. All [0m
[31mpatients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as [0m
[31mvomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician. Hyperkalemia Patients should be told not to use salt substitutes containing [0m
[31mpotassium without consulting their physician. Neutropenia Patients should be told to report promptly any indication of infection [0m[1;31m([0m[31me.g., sore throat, fever[0m[1;31m)[0m[31m which may be a sign of neutropenia. [0m
[31mPregnancy Female patients of childbearing age should be told about the consequences of exposure to enalapril maleate during pregnancy. Discuss treatment options with women planning to become pregnant.[0m
[31mPatients should be asked to report pregnancies to their physicians as soon as possible. ENALAPRIL MALEATE: precautions: NOTE: As with many other drugs, certain advice to patients being treated with [0m
[31menalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects. Drug Interactions [0m
[31mNeprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. Dual Blockade of the Renin-Angiotensin System [0m[1;31m([0m[31mRAS[0m[1;31m)[0m[31m Dual blockade of [0m
[31mthe RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function [0m[1;31m([0m[31mincluding acute renal failure[0m[1;31m)[0m[31m [0m
[31mcompared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. [0m
[31mENALAPRIL MALEATE: precautions: Closely monitor blood pressure, renal function, and electrolytes in patients on enalapril maleate and other agents that affect the RAS. Do not coadminister aliskiren [0m
[31mwith enalapril maleate in patients with diabetes. Avoid use of aliskiren with enalapril maleate in patients with renal impairment [0m[1;31m([0m[31mGFR <[0m[1;31m60[0m[31m mL/min[0m[1;31m)[0m[31m. Hypotension—Patients on Diuretic Therapy Patients on[0m
[31mdiuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril. The [0m
[31mpossibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril. ENALAPRIL [0m
[31mMALEATE: precautions: If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least [0m
[31man additional hour [0m[1;31m([0m[31msee WARNINGS , Hypotension and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Agents Causing Renin Release The antihypertensive effect of enalapril maleate is augmented by antihypertensive agents [0m
[31mthat cause renin release [0m[1;31m([0m[31me.g., diuretics[0m[1;31m)[0m[31m. Nonsteroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-[0m[1;31m2[0m[31m Inhibitors [0m[1;31m([0m[31mCOX-[0m[1;31m2[0m[31m Inhibitors[0m[1;31m)[0m[31m In patients who are elderly, volume-depleted [0m
[1;31m([0m[31mincluding those on diuretic therapy[0m[1;31m)[0m[31m, or with compromised renal function, coadministration of NSAIDs, including selective COX-[0m[1;31m2[0m[31m inhibitors, with ACE inhibitors, including enalapril, may result in [0m
[31mdeterioration of renal function, including possible acute renal failure. These effects are usually reversible.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: LISINOPRIL: drug_interactions: Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline[0m
[31min GFR, end state renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group. In general, avoid combined use of RAS [0m
[31minhibitors. Monitor blood pressure, renal function, and electrolytes in patients on lisinopril and hydrochlorothiazide tablets and other agents that affect the RAS. Do not coadminister aliskiren with [0m
[31mlisinopril and hydrochlorothiazide tablets in patients with diabetes. Avoid use of aliskiren with PRINZIDE in patients with renal impairment [0m[1;31m([0m[31mGFR <[0m[1;31m60[0m[31m ml/min[0m[1;31m)[0m[31m. Other Agents: Lisinopril has been used [0m
[31mconcomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions. LISINOPRIL: drug_interactions: No meaningful clinically important pharmacokinetic [0m
[31minteractions occurred when lisinopril was used concomitantly with propranolol, digoxin, or hydrochlorothiazide. The presence of food in the stomach does not alter the bioavailability of lisinopril. [0m
[31mAgents Increasing Serum Potassium: Lisinopril attenuates potassium loss caused by thiazide-type diuretics. Use of lisinopril with potassium-sparing diuretics [0m[1;31m([0m[31me.g., spironolactone, eplerenone, [0m
[31mtriamterene, or amiloride[0m[1;31m)[0m[31m, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is [0m
[31mindicated, because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. Lithium: Lithium toxicity has been reported in patients receiving [0m
[31mlithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. LISINOPRIL: drug_interactions: Lithium toxicity was usually reversible upon discontinuation of lithium and[0m
[31mthe ACE inhibitor. It is recommended that serum lithium levels be monitored frequently if lisinopril is administered concomitantly with lithium. Gold: Nitritoid reactions [0m[1;31m([0m[31msymptoms include facial [0m
[31mflushing, nausea, vomiting and hypotension[0m[1;31m)[0m[31m have been reported rarely in patients on therapy with injectable gold [0m[1;31m([0m[31msodium aurothiomalate[0m[1;31m)[0m[31m and concomitant ACE inhibitor therapy including lisinopril and[0m
[31mhydrochlorothiazide tablets. mTOR [0m[1;31m([0m[31mmammalian target of rapamycin[0m[1;31m)[0m[31m inhibitors: Patients receiving coadministration of ACE inhibitor and mTOR inhibitor [0m[1;31m([0m[31me.g., temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m [0m
[31mtherapy may be at increased risk for angioedema. [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m Neprilysin Inhibitors: Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema. LISINOPRIL: [0m
[31mdrug_interactions: [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m Hydrochlorothiazide When administered concurrently the following drugs may interact with thiazide diuretics. Alcohol, barbiturates, or narcotics - potentiation of [0m
[31morthostatic hypotension may occur. Antidiabetic drugs [0m[1;31m([0m[31moral agents and insulin[0m[1;31m)[0m[31m - dosage adjustment of the antidiabetic drug may be required. Other antihypertensive drugs - additive effect or [0m
[31mpotentiation. Cholestyramine and colestipol resins - Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol [0m
[31mresins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to [0m[1;31m85[0m[31m% and [0m[1;31m43[0m[31m%, respectively. Corticosteroids, ACTH - intensified electrolyte depletion, [0m
[31mparticularly hypokalemia. Pressor amines [0m[1;31m([0m[31me.g. LISINOPRIL: drug_interactions: norepinephrine[0m[1;31m)[0m[31m - possible decreased response to pressor amines but not sufficient to preclude their use. Skeletal muscle [0m
[31mrelaxants, nondepolarizing [0m[1;31m([0m[31me.g., tubocurarine[0m[1;31m)[0m[31m - possible increased responsiveness to the muscle relaxant. Lithium - should not generally be given with diuretics. Diuretic agents reduce the renal [0m
[31mclearance of lithium and add a high risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with lisinopril and hydrochlorothiazide tablets. [0m
[31mNon-steroidal Anti-inflammatoryDrugs - In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, [0m
[31mpotassium-sparing and thiazide diuretics.         [0m
[31mSOURCE:LISINOPRIL label[0m


[31mCONTENT: ENALAPRIL MALEATE: warnings: WARNINGS Anaphylactoid and Possibly Related Reactions Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and [0m
[31mpolypeptides, including endogenous bradykinin, patients receiving ACE inhibitors [0m[1;31m([0m[31mincluding enalapril maleate[0m[1;31m)[0m[31m may be subject to a variety of adverse reactions, some of them serious. Head and Neck [0m
[31mAngioedema Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors, including enalapril maleate. [0m
[31mThis may occur at any time during treatment. In such cases enalapril maleate should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained [0m
[31mresolution of signs and symptoms has occurred. ENALAPRIL MALEATE: warnings: In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, [0m
[31malthough antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause [0m
[31mairway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution [0m[1;31m1:1000[0m[31m [0m[1;31m([0m[1;31m0.3[0m[31m mL to [0m[1;31m0.5[0m[31m mL[0m[1;31m)[0m[31m and/or measures necessary to ensure a patent airway, should be promptly provided [0m[1;31m([0m[31msee ADVERSE[0m
[31mREACTIONS [0m[1;31m)[0m[31m. Patients receiving coadministration of ACE inhibitor and mTOR [0m[1;31m([0m[31mmammalian target of rapamycin[0m[1;31m)[0m[31m inhibitor [0m[1;31m([0m[31me.g., temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m therapy or a neprilysin inhibitor may [0m
[31mbe at increased risk for angioedema [0m[1;31m([0m[31msee PRECAUTIONS [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: warnings: Intestinal Angioedema Intestinal angioedema has been reported in patients treated with ACE inhibitors. These [0m
[31mpatients presented with abdominal pain [0m[1;31m([0m[31mwith or without nausea or vomiting[0m[1;31m)[0m[31m; in some cases there was no prior history of facial angioedema and C1 esterase levels were normal. The angioedema was [0m
[31mdiagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential [0m
[31mdiagnosis of patients on ACE inhibitors presenting with abdominal pain. Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving [0m
[31man ACE inhibitor [0m[1;31m([0m[31msee INDICATIONS AND USAGE and CONTRAINDICATIONS [0m[1;31m)[0m[31m. Anaphylactoid Reactions During Desensitization Two patients undergoing desensitizing treatment with hymenoptera venom while [0m
[31mreceiving ACE inhibitors sustained life-threatening anaphylactoid reactions. ENALAPRIL MALEATE: warnings: In the same patients, these reactions were avoided when ACE inhibitors were temporarily [0m
[31mwithheld, but they reappeared upon inadvertent rechallenge. Anaphylactoid Reactions During Membrane Exposure Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes [0m
[31mand treated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. Hypotension [0m
[31mExcessive hypotension is rare in uncomplicated hypertensive patients treated with enalapril maleate alone. Patients with heart failure given enalapril maleate commonly have some reduction in blood [0m
[31mpressure, especially with the first dose, but discontinuation of therapy for continuing symptomatic hypotension usually is not necessary when dosing instructions are followed; caution should be [0m
[31mobserved when initiating therapy [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: warnings: Patients at risk for excessive hypotension, sometimes associated with oliguria and/or progressive [0m
[31mazotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high-dose diuretic therapy, recent intensive [0m
[31mdiuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. It may be advisable to eliminate the diuretic [0m[1;31m([0m[31mexcept in patients with heart failure[0m[1;31m)[0m[31m, [0m
[31mreduce the diuretic dose or increase salt intake cautiously before initiating therapy with enalapril maleate in patients at risk for excessive hypotension who are able to tolerate such adjustments [0m
[1;31m([0m[31msee PRECAUTIONS, Drug Interactions and ADVERSE REACTIONS [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: drug_interactions: Other Cardiovascular Agents Enalapril maleate has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking [0m
[31magents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions. Agents Increasing Serum Potassium Enalapril attenuates potassium loss caused by thiazide-type[0m
[31mdiuretics. Potassium-sparing diuretics [0m[1;31m([0m[31me.g., spironolactone, triamterene, or amiloride[0m[1;31m)[0m[31m, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum [0m
[31mpotassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. [0m
[31mPotassium-sparing agents should generally not be used in patients with heart failure receiving enalapril maleate. ENALAPRIL MALEATE: drug_interactions: Lithium Lithium toxicity has been reported in [0m
[31mpatients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of lithium toxicity have been reported in patients receiving concomitant [0m
[31menalapril maleate and lithium and were reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly [0m
[31mwith lithium. Gold Nitritoid reactions [0m[1;31m([0m[31msymptoms include facial flushing, nausea, vomiting and hypotension[0m[1;31m)[0m[31m have been reported rarely in patients on therapy with injectable gold [0m[1;31m([0m[31msodium [0m
[31maurothiomalate[0m[1;31m)[0m[31m and concomitant ACE inhibitor therapy including enalapril maleate. mTOR [0m[1;31m([0m[31mMammalian Target of Rapamycin[0m[1;31m)[0m[31m Inhibitors Patients receiving coadministration of ACE inhibitor and mTOR [0m
[31minhibitor [0m[1;31m([0m[31me.g. ENALAPRIL MALEATE: drug_interactions: temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m therapy may be at increased risk for angioedema [0m[1;31m([0m[31msee WARNINGS, Head and Neck Angioedema [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ATENOLOL: spl_unclassified_section: POTENTIAL ADVERSE EFFECTS In addition, a variety of adverse effects have been reported with other beta-adrenergic blocking agents, and may be considered [0m
[31mpotential adverse effects of atenolol. Hematologic Agranulocytosis. Allergic Fever, combined with aching and sore throat, laryngospasm, and respiratory distress. Central Nervous System Reversible [0m
[31mmental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation of time and place; short-term memory loss; emotional lability with slightly clouded sensorium; [0m
[31mand, decreased performance on neuropsychometrics. Gastrointestinal Mesenteric arterial thrombosis, ischemic colitis. Other Erythematous rash. Miscellaneous There have been reports of skin rashes [0m
[31mand/or dry eyes associated with the use of beta-adrenergic blocking drugs. The reported incidence is small, and in most cases, the symptoms have cleared when treatment was withdrawn. ATENOLOL: [0m
[31mspl_unclassified_section: Discontinuance of the drug should be considered if any such reaction is not otherwise explicable. Patients should be closely monitored following cessation of therapy [0m[1;31m([0m[31msee [0m
[31mDOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. The oculomucocutaneous syndrome associated with the beta blocker practolol has not been reported with atenolol. Furthermore, a number of patients who had previously [0m
[31mdemonstrated established practolol reactions were transferred to atenolol therapy with subsequent resolution or quiescence of the reaction.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mTENOLOL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the ATENOLOL label does not indicate that atenolol increases the risk of angioedema. The adverse reactions section of the label lists various potential side [0m
[32meffects, but angioedema is not mentioned as one of them. However, it is important to note that while atenolol itself may not be associated with an increased risk of angioedema, other beta blockers or [0m
[32mmedications in the same class as atenolol, such as ACE inhibitors [0m[1;32m([0m[32me.g., lisinopril and enalapril[0m[1;32m)[0m[32m, have been reported to cause angioedema. Patients taking beta blockers who have a history of [0m
[32manaphylactic reactions to a variety of allergens may have a more severe reaction on repeated challenge and may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.[0m

[32mSOURCE: ATENOLOL label[0m
[32mEXTRACT_START_END: ATENOLOL: adverse_reactions: [0m[32m...[0m[32m and dry mouth. Atenolol, like other beta blockers, has been associated with [0m[32m...[0m[32m Raynaud’s phenomenon.[0m
*[1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the ATENOLOL label does not indicate [0m
[34mthat atenolol increases the risk of angioedema. The adverse reactions section of the label lists various potential side effects, but angioedema is not mentioned as one of them. However, it is [0m
[34mimportant to note that while atenolol itself may not be associated with an increased risk of angioedema, other beta blockers or medications in the same class as atenolol, such as ACE inhibitors [0m[1;34m([0m[34me.g.,[0m
[34mlisinopril and enalapril[0m[1;34m)[0m[34m, have been reported to cause angioedema. Patients taking beta blockers who have a history of anaphylactic reactions to a variety of allergens may have a more severe reaction [0m
[34mon repeated challenge and may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.[0m

[34mSOURCE: ATENOLOL label[0m
[34mEXTRACT_START_END: ATENOLOL: adverse_reactions: [0m[34m...[0m[34m and dry mouth. Atenolol, like other beta blockers, has been associated with [0m[34m...[0m[34m Raynaud’s phenomenon.[0m
 [1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ATENOLOL increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if ATENOLOL increases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the ATENOLOL label does not indicate an increased risk of angioedema. The adverse reactions section does not mention angioedema as a side effect."[0m[32m,[0m
[32m      [0m[32m"FDAHandler also noted that while atenolol itself may not be associated with an increased risk of angioedema, other medications in the same class, such as ACE inhibitors, have been reported to [0m
[32mcause angioedema."[0m[32m,[0m
[32m      [0m[32m"Patients taking beta blockers who have a history of anaphylactic reactions to a variety of allergens may have a more severe reaction on repeated challenge and may be unresponsive to the usual [0m
[32mdoses of epinephrine used to treat allergic reactions."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"According to the FDA label data provided by FDAHandler, ATENOLOL does not increase the risk of angioedema, as angioedema is not listed as a side effect in the adverse reactions section [0m
[32mof the label. However, it is important to note that other medications in the same class as atenolol, such as ACE inhibitors, have been associated with angioedema. Additionally, patients taking beta [0m
[32mblockers with a history of anaphylactic reactions may have a more severe reaction and may be unresponsive to usual treatments for allergic reactions."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ATENOLOL increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if ATENOLOL increases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the ATENOLOL label does not indicate an increased risk of angioedema. The adverse reactions section does not mention angioedema as a side effect."[0m[34m,[0m
[34m      [0m[34m"FDAHandler also noted that while atenolol itself may not be associated with an increased risk of angioedema, other medications in the same class, such as ACE inhibitors, have been reported to [0m
[34mcause angioedema."[0m[34m,[0m
[34m      [0m[34m"Patients taking beta blockers who have a history of anaphylactic reactions to a variety of allergens may have a more severe reaction on repeated challenge and may be unresponsive to the usual [0m
[34mdoses of epinephrine used to treat allergic reactions."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"According to the FDA label data provided by FDAHandler, ATENOLOL does not increase the risk of angioedema, as angioedema is not listed as a side effect in the adverse reactions section [0m
[34mof the label. However, it is important to note that other medications in the same class as atenolol, such as ACE inhibitors, have been associated with angioedema. Additionally, patients taking beta [0m
[34mblockers with a history of anaphylactic reactions may have a more severe reaction and may be unresponsive to usual treatments for allergic reactions."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ATENOLOL increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if ATENOLOL increases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler responded that the ATENOLOL label does not indicate an increased risk of angioedema. The adverse reactions section does not mention angioedema as a side effect.[0m
[1;31m3[0m[31m. FDAHandler also noted that while atenolol itself may not be associated with an increased risk of angioedema, other medications in the same class, such as ACE inhibitors, have been reported to cause[0m
[31mangioedema.[0m
[1;31m4[0m[31m. Patients taking beta blockers who have a history of anaphylactic reactions to a variety of allergens may have a more severe reaction on repeated challenge and may be unresponsive to the usual doses[0m
[31mof epinephrine used to treat allergic reactions.[0m
[31m        -----[0m
[31m        Final answer: According to the FDA label data provided by FDAHandler, ATENOLOL does not increase the risk of angioedema, as angioedema is not listed as a side effect in the adverse reactions [0m
[31msection of the label. However, it is important to note that other medications in the same class as atenolol, such as ACE inhibitors, have been associated with angioedema. Additionally, patients taking[0m
[31mbeta blockers with a history of anaphylactic reactions may have a more severe reaction and may be unresponsive to usual treatments for allergic reactions.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-ATENOLOL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe final answer to the question [0m[32m"Does ATENOLOL increase or decrease the risk of angioedema?"[0m[32m is that according to the FDA label data provided by FDAHandler, ATENOLOL does not increase the risk of [0m
[32mangioedema. Angioedema is not listed as a side effect in the adverse reactions section of the ATENOLOL label. However, it is important to note that other medications in the same class as atenolol, [0m
[32msuch as ACE inhibitors, have been associated with angioedema. Additionally, patients taking beta blockers with a history of anaphylactic reactions may have a more severe reaction and may be [0m
[32munresponsive to usual treatments for allergic reactions.[0m
